Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06787144 | ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants(CML) | recruiting | Phase 1 | 21 | Enliven TherapeuticsINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06199557 | A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients(HUVAMER) | recruiting | Phase 1 / Phase 2 | 48 | Haukeland University HospitalOTHER | 1 | Jun 29, 2025 |
| clinicaltrials |
| NCT07008885 | BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07009002 | BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07036250 | Clinical Study of U32 in Patients With Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07032129 | Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma(BAH2573) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07028073 | A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 78 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT05219721 | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | recruiting | Phase 1 | 18 | Chunrui LiOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07014449 | Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 18 | Hangzhou Weben Pharma Co., LtdINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06987916 | Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 50 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06119685 | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | recruiting | Phase 1 / Phase 2 | 128 | Indapta Therapeutics, INC.INDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06880354 | A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 37 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06757855 | Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML | recruiting | Phase 1 / Phase 2 | 29 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06014073 | TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06323525 | TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT05759793 | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | recruiting | Phase 1 | 12 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | May 20, 2025 | clinicaltrials |
| NCT06971523 | A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies | recruiting | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT05326243 | Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Pell Bio-Med Technology Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT06925464 | CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas | recruiting | Phase 1 / Phase 2 | 36 | Beijing GoBroad HospitalOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06967038 | Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome(CAR-NK) | recruiting | Phase 1 / Phase 2 | 6 | Bangdong GongOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06634394 | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | recruiting | Phase 1 | 39 | Aptevo TherapeuticsINDUSTRY | 1 | May 11, 2025 | clinicaltrials |
| NCT06752746 | A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera | recruiting | Phase 1 | 108 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | May 11, 2025 | clinicaltrials |
| NCT05908409 | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies(CASSANDRA) | recruiting | Phase 1 / Phase 2 | 37 | IDP Discovery Pharma S.L.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT05863234 | Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia | recruiting | Phase 1 / Phase 2 | 7 | Hiroshima University HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05943067 | CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT(CD45RADLIHaplo) | recruiting | Phase 1 / Phase 2 | 60 | University Hospital TuebingenOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT03571568 | A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL | recruiting | Phase 1 / Phase 2 | 140 | BioInvent International ABINDUSTRY | 6 | Apr 24, 2025 | clinicaltrials |
| NCT06297941 | Study of REM-422 in Patients With AML or Higher Risk MDS | recruiting | Phase 1 | 100 | Remix TherapeuticsINDUSTRY | 2 | Apr 23, 2025 | clinicaltrials |
| NCT06118788 | Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 24 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 1 | Apr 17, 2025 | clinicaltrials |
| NCT04494503 | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | recruiting | Phase 1 / Phase 2 | 123 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06462365 | Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) | recruiting | Phase 1 | 36 | Tr1X, Inc.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT05423691 | Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs(TREG108) | recruiting | Phase 1 | 24 | Cellenkos, Inc.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04215809 | Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL | recruiting | Phase 1 | 144 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Apr 10, 2025 | clinicaltrials |
| NCT06914037 | A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies(COURAGE) | recruiting | Phase 1 | 24 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06911710 | The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors(CAR-T) | recruiting | Phase 1 / Phase 2 | 90 | Tianjin Medical University General HospitalOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06760039 | Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL | recruiting | Phase 1 / Phase 2 | 112 | Sun Yat-sen UniversityOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06484829 | Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 144 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06313957 | A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 42 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT06245746 | UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia | recruiting | Phase 1 | 9 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05828459 | First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors | recruiting | Phase 1 | 150 | Onward TherapeuticsINDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05947344 | A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) | recruiting | Phase 1 | 84 | Zhejiang ACEA Pharmaceutical Co. Ltd.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT05190471 | A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | recruiting | Phase 1 | 48 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06613217 | Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia | recruiting | Phase 1 | 35 | Pacylex PharmaceuticalsINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06060782 | Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine(TCCA) | recruiting | Phase 1 | 28 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT05472558 | Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL | recruiting | Phase 1 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT05487170 | A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | recruiting | Phase 1 / Phase 2 | 32 | Ranok Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 2 | Mar 4, 2025 | clinicaltrials |
| NCT04271644 | BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | recruiting | Phase 1 / Phase 2 | 80 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04776330 | a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | recruiting | Phase 1 / Phase 2 | 80 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06299462 | PTCy and ATG for MSD and MUD Transplants | recruiting | Phase 1 / Phase 2 | 50 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06835140 | CD123-CD16-NK Cells Immunotherapy for AML(CD123-CD16-NK) | recruiting | Phase 1 | 9 | Chunji GaoOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06484816 | TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies | recruiting | Phase 1 | 90 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 1, 2025source: clinicaltrials